Legend Biotech (LEGN) Competitors $37.50 -0.21 (-0.56%) Closing price 08/15/2025 04:00 PM EasternExtended Trading$37.40 -0.10 (-0.26%) As of 08/15/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock LEGN vs. BNTX, INSM, SMMT, TEVA, GMAB, ASND, VTRS, RDY, QGEN, and MRNAShould you be buying Legend Biotech stock or one of its competitors? The main competitors of Legend Biotech include BioNTech (BNTX), Insmed (INSM), Summit Therapeutics (SMMT), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), Ascendis Pharma A/S (ASND), Viatris (VTRS), Dr. Reddy's Laboratories (RDY), Qiagen (QGEN), and Moderna (MRNA). These companies are all part of the "pharmaceutical products" industry. Legend Biotech vs. Its Competitors BioNTech Insmed Summit Therapeutics Teva Pharmaceutical Industries Genmab A/S Ascendis Pharma A/S Viatris Dr. Reddy's Laboratories Qiagen Moderna Legend Biotech (NASDAQ:LEGN) and BioNTech (NASDAQ:BNTX) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, dividends, institutional ownership, valuation and risk. Do analysts prefer LEGN or BNTX? Legend Biotech presently has a consensus price target of $72.38, suggesting a potential upside of 93.00%. BioNTech has a consensus price target of $135.80, suggesting a potential upside of 19.63%. Given Legend Biotech's stronger consensus rating and higher probable upside, analysts plainly believe Legend Biotech is more favorable than BioNTech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Legend Biotech 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.00BioNTech 0 Sell rating(s) 4 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 2.76 Which has more risk and volatility, LEGN or BNTX? Legend Biotech has a beta of 0.26, meaning that its stock price is 74% less volatile than the S&P 500. Comparatively, BioNTech has a beta of 1.23, meaning that its stock price is 23% more volatile than the S&P 500. Does the media prefer LEGN or BNTX? In the previous week, Legend Biotech had 13 more articles in the media than BioNTech. MarketBeat recorded 24 mentions for Legend Biotech and 11 mentions for BioNTech. Legend Biotech's average media sentiment score of 0.40 beat BioNTech's score of 0.40 indicating that Legend Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Legend Biotech 5 Very Positive mention(s) 3 Positive mention(s) 10 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral BioNTech 2 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 3 Negative mention(s) 2 Very Negative mention(s) Neutral Is LEGN or BNTX more profitable? BioNTech has a net margin of -12.20% compared to Legend Biotech's net margin of -40.83%. BioNTech's return on equity of -1.84% beat Legend Biotech's return on equity.Company Net Margins Return on Equity Return on Assets Legend Biotech-40.83% -32.00% -20.07% BioNTech -12.20%-1.84%-1.59% Do institutionals and insiders hold more shares of LEGN or BNTX? 70.9% of Legend Biotech shares are held by institutional investors. Comparatively, 15.5% of BioNTech shares are held by institutional investors. 0.0% of Legend Biotech shares are held by insiders. Comparatively, 19.2% of BioNTech shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has better valuation and earnings, LEGN or BNTX? Legend Biotech has higher earnings, but lower revenue than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Legend Biotech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLegend Biotech$627.24M10.99-$177.03M-$0.88-42.61BioNTech$2.98B9.17-$719.92M-$1.60-70.95 SummaryLegend Biotech beats BioNTech on 10 of the 17 factors compared between the two stocks. Get Legend Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for LEGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LEGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LEGN vs. The Competition Export to ExcelMetricLegend BiotechMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.93B$3.10B$5.68B$9.81BDividend YieldN/A2.23%3.79%4.12%P/E Ratio-42.6120.8931.0825.11Price / Sales10.99366.96467.01193.48Price / CashN/A42.3037.4059.05Price / Book6.658.659.096.18Net Income-$177.03M-$54.65M$3.26B$265.11M7 Day Performance1.35%6.56%7.36%4.21%1 Month Performance-5.66%7.53%5.47%2.01%1 Year Performance-34.08%13.69%30.61%23.75% Legend Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LEGNLegend Biotech3.7481 of 5 stars$37.50-0.6%$72.38+93.0%-32.7%$6.93B$627.24M-42.612,609News CoverageEarnings ReportAnalyst ForecastBNTXBioNTech1.6219 of 5 stars$109.26-2.1%$135.91+24.4%+30.1%$26.27B$2.98B-68.296,772Analyst ForecastAnalyst RevisionINSMInsmed4.1191 of 5 stars$112.89+3.0%$112.71-0.2%+72.4%$21.42B$398.11M-19.771,271Trending NewsAnalyst ForecastAnalyst RevisionSMMTSummit Therapeutics2.5611 of 5 stars$28.25-1.4%$34.67+22.7%+124.9%$20.98BN/A-83.09110News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionTEVATeva Pharmaceutical Industries3.8775 of 5 stars$16.41+0.3%$24.71+50.6%-2.5%$18.83B$16.54B-102.5836,830News CoveragePositive NewsGMABGenmab A/S3.984 of 5 stars$21.08-1.6%$37.80+79.3%-14.3%$13.52B$3.26B10.592,682Positive NewsAnalyst ForecastAnalyst RevisionASNDAscendis Pharma A/S2.4129 of 5 stars$195.97+2.3%$239.80+22.4%+42.2%$11.98B$393.54M-37.981,017VTRSViatris2.0503 of 5 stars$9.86+1.6%$10.40+5.5%-9.1%$11.57B$14.74B-3.4032,000Insider TradeRDYDr. Reddy's Laboratories2.9387 of 5 stars$13.81+0.0%$16.95+22.8%-12.8%$11.53B$334.26B20.9227,811News CoverageAnalyst RevisionQGENQiagen3.659 of 5 stars$48.02-0.1%$49.69+3.5%+9.3%$10.67B$1.98B28.375,765News CoverageMRNAModerna4.3959 of 5 stars$25.47-2.5%$43.59+71.1%-67.7%$9.91B$3.24B-3.385,800Options Volume Related Companies and Tools Related Companies BNTX Alternatives INSM Alternatives SMMT Alternatives TEVA Alternatives GMAB Alternatives ASND Alternatives VTRS Alternatives RDY Alternatives QGEN Alternatives MRNA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LEGN) was last updated on 8/16/2025 by MarketBeat.com Staff From Our PartnersWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredThe Debt Crisis Is Coming—Will You Be Ready?A full-blown "economic heart attack" is coming—and the markets aren't ready. The problem? Exploding U.S. de...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Legend Biotech Corporation Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Legend Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access